GLP-1 weight-management drugs follow strict FDA criteria. Wegovy (semaglutide 2.4 mg) is approved for adults with BMI ≥30 or BMI ≥27 with at least one weight-related comorbid condition — type 2 diabetes, hypertension, dyslipidemia, or obstructive sleep apnea. Zepbound (tirzepatide) follows identical eligibility for weight management. Pediatric Wegovy is approved at age 12+ with BMI at or above the 95th percentile.
For type 2 diabetes (separate indication), Ozempic and Mounjaro have no BMI requirement — they are indicated based on A1C and prior treatment failure.
Not eligible: pregnancy, personal/family history of medullary thyroid carcinoma (MTC), multiple endocrine neoplasia syndrome type 2 (MEN 2), prior pancreatitis, or active gallbladder disease.